May 12, 2026 | FDA Commissioner Makary Resigns; BMS-Hengrui $15.2B 13-Asset Alliance

FDA Commissioner Makary resigns; Kyle Diamantas steps in as acting chief amid regulatory upheaval. BMS and Hengrui ink $15.2B alliance across 13 programs in oncology, hematology, and immunology. Lilly's Foundayo maintains 82% of weight loss vs. Wegovy switch in ATTAIN-MAINTAIN Phase 3 data.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Marty Makary, Kyle Diamantas, Bristol Myers Squibb, BMS, Hengrui Pharma, Eli Lilly, Foundayo, orforglipron, Zepbound, tirzepatide, Wegovy, Novo Nordisk, Rigel Pharmaceuticals, Veppanu, vepdegestrant, Pfizer, Arvinas, PROTAC, Alkermes, Lumryz, Avadel, idiopathic hypersomnia, obesity, weight loss, breast cancer, BioMarin, Amicus, GSK, Sino Biopharmaceutical, bepirovirsen, Isomorphic Labs, Bayer, Leqembi, Critical Medicines Act, hantavirus, Lilly, AstraZeneca